Pathways Panel

The Problem:​

So far, success of precision medicine initiatives has been limited, why?​

  1. DNA-based, even though a DNA mutation does not imply downstream pathway activation​

  2. Focused only on one gene/one protein​

  3. Focused only on one molecular pathway​

Our Solution:​

novel, multi-plexed, complementary diagnostic that integrates RNA and Protein information to determine pathway activation and identify the right targeted therapy for the right patient.​